1. Home
  2. Stock quotes
  3. Marker Therapeutics
  4. Financial Statements
  5. Balance Sheet
Marker Therapeutics logo
Marker Therapeutics MRKR
$ 1.47 1.38%

Quarterly report 2026-Q1
added 05-15-2026

report update icon

Marker Therapeutics Balance Sheet 2011-2026 | MRKR

Annual Balance Sheet Marker Therapeutics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999

Net Debt

 - - - -4.17 M -30.5 M -9.1 M -43.4 M -61.7 M -5.12 M -7.85 M -6.52 M -89 K 3.43 M 1.4 M 856 K - - - - - - - - - - - -

Long Term Debt

 - - - 7.04 M 11.2 M - - - - - - - - - - - - - - - - - - - - - -

Long Term Debt Current

 - - - 577 K 620 K 389 K 204 K - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

 - - - 7.04 M 11.2 M 11.9 M 280 K - - - - - - - - - - - - - - - - - - - -

Total Current Liabilities

 2.27 M 3.46 M 3.07 M 7.78 M 12.9 M 6.4 M 1.99 M 2.8 M 1.52 M 1.74 M 28 M 1.25 M 8.85 M 5.77 M 3.8 M 3.98 M - - - - - - - - - - -

Total Liabilities

 2.27 M 3.46 M 3.07 M 14.8 M 24.1 M 18.3 M 2.27 M 2.8 M 1.52 M 1.74 M 28 M 1.25 M 8.85 M 5.77 M 3.8 M - - - - - - - - - - - -

Deferred Revenue

 975 K - - - 1.15 M - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

 -459 M -447 M -436 M -428 M -398 M -356 M -328 M -306 M -157 M -146 M -134 M -86.3 M -55.4 M -49.6 M -43.7 M - - - - - - - - - - - -

Total Assets

 19.1 M 22 M 17.1 M 34.4 M 68.1 M 45.6 M 46.4 M 62.1 M 5.18 M 7.92 M 6.65 M 224 K 77 K 104 K 340 K 116 K - - - - - - - - - - -

Cash and Cash Equivalents

 16.1 M 19.2 M 15.1 M 11.8 M 42.4 M 21.4 M 43.9 M 61.7 M 5.13 M 7.85 M 6.58 M 142 K 48.6 K 33.8 K 250 K 23.5 K 141 K - - - - - - - - - -

Book Value

 16.8 M 18.6 M 14.1 M 19.6 M 44 M 27.3 M 44.1 M 59.3 M 3.66 M 6.18 M -21.4 M -1.02 M -8.77 M -5.67 M -3.46 M 116 K - - - - - - - - - - -

Total Shareholders Equity

 16.8 M 18.6 M 14.1 M 19.6 M 44 M 27.3 M 44.1 M 59.3 M 3.66 M 6.18 M -21.4 M -1.02 M -8.77 M -6.04 M -3.46 M -3.87 M -1.78 M -3.02 M -1.67 M -3 M -2.22 M -2.44 M -644 K 466 K -74 K 252 K 100 K

All numbers in USD currency

Quarterly Balance Sheet Marker Therapeutics

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

 - - - - - - - - - - - 6.82 M 7.04 M 7.23 M 10.8 M 11 M 11.2 M 11.4 M 11.6 M 11.7 M 11.9 M 11.9 M 11.9 M 11.9 M 280 K 280 K 280 K 280 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

 - - - - - - - - - - - 6.82 M 7.04 M 7.23 M 10.8 M 11 M 11.2 M 11.4 M 11.6 M 11.7 M 11.9 M 11.9 M 11.9 M 11.9 M 280 K 280 K 280 K 280 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

 3.64 M 3.35 M 4.28 M 2.5 M 3.46 M 3.46 M 1.97 M 2.3 M 3.07 M 2.78 M 2.92 M 12 M 14.8 M 18.5 M 24.3 M 19.3 M 24.1 M 19.7 M 17.2 M 15.9 M 18.3 M 18.3 M 18.3 M 18.3 M 2.27 M 2.27 M 2.27 M 2.27 M 2.8 M 2.8 M 2.8 M 2.8 M 1.52 M 1.52 M 1.52 M 1.52 M 1.74 M 1.74 M 1.74 M 1.74 M - - - - - - - - - - - - - - - - - 2.27 M 1.87 M -

Deferred Revenue

 - 1.35 M 1.35 M - - - - - - 108 K - - - - - 182 K 1.15 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

 -462 M -457 M -455 M -451 M -447 M -443 M -441 M -439 M -436 M -433 M -431 M -433 M -428 M -424 M -417 M -408 M -398 M -388 M -376 M -365 M -356 M -356 M -356 M -356 M -328 M -328 M -328 M -328 M -306 M -306 M -306 M -306 M -157 M -157 M -157 M -157 M -146 M -146 M -146 M -146 M -134 M -134 M -134 M -134 M -86.3 M -86.3 M -86.3 M -86.3 M -55.4 M -58.3 K - - - - - - - - - -

Total Assets

 17.4 M 21.7 M 14.8 M 17 M 22 M 10.9 M 11.7 M 14.1 M 17.1 M 19.5 M 22 M 27.9 M 34.4 M 41.1 M 52.3 M 55 M 68.1 M 71.9 M 80.5 M 88.4 M 45.6 M 45.6 M 45.6 M 45.6 M 46.4 M 46.4 M 46.4 M 46.4 M 62.1 M 62.1 M 62.1 M 62.1 M 5.18 M 5.18 M 5.18 M 5.18 M 7.92 M 7.92 M 7.92 M 7.92 M 6.65 M 6.65 M - 1.54 M 224 K - - 224 K 77 K 150 K - 185 K 87.4 K 87.4 K 87.4 K 87.4 K 308 K 340 K 340 K 340 K

Cash and Cash Equivalents

 14.9 M 17.6 M 10.5 M 13.7 M 19.2 M 9 M 7.8 M 11.3 M 15.1 M 17.5 M 18.1 M 6.4 M 11.8 M 18.1 M 25.8 M 28.8 M 42.4 M 48.7 M 57.2 M 64.5 M 21.4 M 21.4 M 21.4 M 21.4 M 43.9 M 43.9 M 43.9 M 43.9 M 61.7 M 61.7 M 61.7 M 61.7 M 5.13 M 5.13 M 5.13 M 5.13 M 7.85 M 7.85 M 7.85 M 7.85 M 6.58 M 6.58 M 6.58 M 6.58 M 142 K 614 K 142 K 142 K 48.6 K 48.6 K 48.6 K 48.6 K 33.8 K 33.8 K 33.8 K 33.8 K 250 K 250 K 250 K 250 K

Book Value

 13.8 M 18.4 M 10.5 M 14.5 M 18.6 M 7.45 M 9.7 M 11.8 M 14.1 M 16.7 M 19 M 15.9 M 19.6 M 22.6 M 28 M 35.7 M 44 M 52.3 M 63.2 M 72.5 M 27.3 M 27.3 M 27.3 M 27.3 M 44.1 M 44.1 M 44.1 M 44.1 M 59.3 M 59.3 M 59.3 M 59.3 M 3.66 M 3.66 M 3.66 M 3.66 M 6.18 M 6.18 M 6.18 M 6.18 M 6.65 M 6.65 M - 1.54 M 224 K - - 224 K 77 K 150 K - 185 K 87.4 K 87.4 K 87.4 K 87.4 K 308 K -1.93 M -1.53 M 340 K

Total Shareholders Equity

 13.8 M 18.4 M 10.5 M 14.5 M 18.6 M 7.45 M 9.7 M 11.8 M 14.1 M 16.7 M 19 M 15.9 M 19.6 M 22.6 M 28 M 35.7 M 44 M 52.3 M 63.2 M 72.5 M 27.3 M 27.3 M 27.3 M 27.3 M 44.1 M 44.1 M 44.1 M 44.1 M 59.3 M 59.3 M 59.3 M 59.3 M 3.66 M 3.66 M 3.66 M 3.66 M 6.18 M 6.18 M 6.18 M 6.18 M -21.4 M -21.4 M -21.4 M -21.4 M -1.02 M -1.02 M -1.02 M -1.02 M -8.77 M -8.77 M -8.77 M -8.77 M -6.04 M -6.04 M -6.04 M -6.04 M -3.46 M -3.46 M -3.46 M -3.46 M

All numbers in USD currency

Balance Sheet is a fundamental financial report of Marker Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
FSD Pharma FSD Pharma
HUGE
 		- 5743.5 % $ 69.7 M canadaCanada
MorphoSys AG MorphoSys AG
MOR
 		- 2.43 % $ 254 M germanyGermany
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
 		- 1.35 % $ 17.8 M chinaChina
AgeX Therapeutics AgeX Therapeutics
AGE
 		- -10.17 % $ 12.2 K usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
 		$ 1.72 4.57 % $ 201 M usaUSA
I-Mab I-Mab
IMAB
 		- - $ 866 M chinaChina
Celldex Therapeutics Celldex Therapeutics
CLDX
 		$ 31.9 3.39 % $ 2.12 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
 		- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
 		- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
 		- 2.54 % $ 160 B franceFrance
BioNTech SE BioNTech SE
BNTX
 		$ 94.08 1.98 % $ 22.7 B germanyGermany
AstraZeneca PLC AstraZeneca PLC
AZN
 		- - $ 96.9 B britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
 		- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
 		- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
 		- 0.74 % $ 768 M israelIsrael
Compugen Ltd. Compugen Ltd.
CGEN
 		$ 2.68 0.75 % $ 250 M israelIsrael
Abcam plc Abcam plc
ABCM
 		- - $ 4.9 B britainBritain
Galera Therapeutics Galera Therapeutics
GRTX
 		- -32.59 % $ 7.61 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
 		- -18.52 % $ 27.3 M britainBritain
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
 		$ 0.75 9.37 % $ 34.3 M israelIsrael
Esperion Therapeutics Esperion Therapeutics
ESPR
 		$ 3.13 0.32 % $ 651 M usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
 		$ 31.76 1.5 % $ 855 M usaUSA
Affimed N.V. Affimed N.V.
AFMD
 		- -34.95 % $ 21.5 M germanyGermany
Forte Biosciences Forte Biosciences
FBRX
 		$ 22.94 4.54 % $ 297 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
 		- - - russiaRussia
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
 		- - $ 231 M usaUSA
Celyad Oncology SA Celyad Oncology SA
CYAD
 		- - $ 12.5 M belgiumBelgium
Berkeley Lights Berkeley Lights
BLI
 		- -7.31 % $ 87 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
 		- - $ 344 M usaUSA
IMV IMV
IMV
 		- - $ 13.1 M canadaCanada
Akero Therapeutics Akero Therapeutics
AKRO
 		- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
 		- 0.23 % $ 488 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
 		- - $ 7.46 M israelIsrael
Grifols, S.A. Grifols, S.A.
GRFS
 		$ 8.16 1.87 % $ 5.55 B spainSpain
Hutchison China MediTech Limited Hutchison China MediTech Limited
HCM
 		$ 11.93 1.53 % $ 10.2 B chinaChina
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
 		- -4.36 % $ 27 M usaUSA
Freeline Therapeutics Holdings plc Freeline Therapeutics Holdings plc
FRLN
 		- - $ 384 M britainBritain
Heron Therapeutics Heron Therapeutics
HRTX
 		$ 0.92 3.78 % $ 153 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
 		- - $ 3.37 B chinaChina
Anika Therapeutics Anika Therapeutics
ANIK
 		$ 14.69 -1.36 % $ 211 M usaUSA
Advaxis Advaxis
ADXS
 		- -9.65 % $ 45.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
 		- 5.93 % $ 314 M canadaCanada
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
 		- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
 		- - $ 867 M germanyGermany
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
 		- - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
 		- 1.93 % $ 17.4 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
 		$ 3.42 -0.73 % $ 5.63 M israelIsrael
Aptose Biosciences Aptose Biosciences
APTO
 		- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
 		- -39.0 % $ 4.57 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
 		- -0.23 % $ 916 M usaUSA